Impact of L‑type amino acid transporter 3 on the prognosis of hepatocellular carcinoma
The aim of the present study was to investigate the impact of L-type amino acid transporter 3 (LAT3) expression on the prognosis of hepatocellular carcinoma (HCC). A total of 135 patients who had undergone initial hepatic resection for HCC at Tokushima University Hospital (Tokushima, Japan) were enr...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2022-11, Vol.24 (5), p.1, Article 418 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 1 |
| container_title | Oncology letters |
| container_volume | 24 |
| creator | Selenge, Baasansvren Yamada, Shinichiro Morine, Yuji Ikemoto, Tetsuya Saito, Yu Takasu, Chie Teraoku, Hiroki Shimada, Mitsuo |
| description | The aim of the present study was to investigate the impact of L-type amino acid transporter 3 (LAT3) expression on the prognosis of hepatocellular carcinoma (HCC). A total of 135 patients who had undergone initial hepatic resection for HCC at Tokushima University Hospital (Tokushima, Japan) were enrolled in the present study. Immunohistochemical analysis of LAT3 and phosphorylated AKT (p-AKT) was performed using resected specimens. Clinicopathological factors, including prognosis, were compared between the LAT3-high and -low expression groups. The results demonstrated that the LAT3-high group showed significantly higher protein induced by vitamin K absence-II levels (P=0.01) compared with the LAT3-low group. The LAT3-high group showed significantly worse prognosis compared with the LAT3-low group regarding cancer-specific survival and disease-free survival (P |
| doi_str_mv | 10.3892/ol.2022.13538 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9555019</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A724663625</galeid><sourcerecordid>A724663625</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-4b94d184870a6aedd527e4071511e3dabcac257c00113dde60b843a96f1eafd03</originalsourceid><addsrcrecordid>eNptks1q3TAQhU1oISHJsntBoTvf6seS7U0hhP4ELnTTQHZirjS-VpAlV5IL2fUV-op9kvomIe2FSgsNmu8cZuBU1RtGN6Lr-fvoN5xyvmFCiu6kOmNtz2tGO_7qpW6b0-oy53u6HqlY16mz6u5mmsEUEgey_f3zV3mYkcDkQiRgnCUlQchzTAUTESQGUkYkc4r7ELPLB9WIM5Ro0PvFQyIGklnVE1xUrwfwGS-f3_Pq9tPHb9df6u3XzzfXV9vayIaVutn1jWVd07UUFKC1krfY0JZJxlBY2BkwXLaGUsaEtajormsE9GpgCIOl4rz68OQ7L7sJrcGwzuz1nNwE6UFHcPq4E9yo9_GH7qWUlPWrwdtngxS_L5iLvo9LCuvMmre8YaJRSv6l9uBRuzDE1cxMLht9tVJKCcUP1OY_1HotTs7EgINb_48E7_4RjAi-jDn6pbgY8jFYP4EmxZwTDi8bMqoPAdDR60MA9GMAxB-Ge6NO</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2724134665</pqid></control><display><type>article</type><title>Impact of L‑type amino acid transporter 3 on the prognosis of hepatocellular carcinoma</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Selenge, Baasansvren ; Yamada, Shinichiro ; Morine, Yuji ; Ikemoto, Tetsuya ; Saito, Yu ; Takasu, Chie ; Teraoku, Hiroki ; Shimada, Mitsuo</creator><creatorcontrib>Selenge, Baasansvren ; Yamada, Shinichiro ; Morine, Yuji ; Ikemoto, Tetsuya ; Saito, Yu ; Takasu, Chie ; Teraoku, Hiroki ; Shimada, Mitsuo</creatorcontrib><description>The aim of the present study was to investigate the impact of L-type amino acid transporter 3 (LAT3) expression on the prognosis of hepatocellular carcinoma (HCC). A total of 135 patients who had undergone initial hepatic resection for HCC at Tokushima University Hospital (Tokushima, Japan) were enrolled in the present study. Immunohistochemical analysis of LAT3 and phosphorylated AKT (p-AKT) was performed using resected specimens. Clinicopathological factors, including prognosis, were compared between the LAT3-high and -low expression groups. The results demonstrated that the LAT3-high group showed significantly higher protein induced by vitamin K absence-II levels (P=0.01) compared with the LAT3-low group. The LAT3-high group showed significantly worse prognosis compared with the LAT3-low group regarding cancer-specific survival and disease-free survival (P<0.05). Multivariate analysis revealed that high LAT3 expression and multiple tumors were independent prognostic factors for cancer-specific survival. Furthermore, the rate of p-AKT-positive cases was higher in the LAT3-high group than in the LAT3-low group. Overall, these findings suggested that LAT3 expression was associated with poor prognosis of HCC and high p-AKT expression.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2022.13538</identifier><language>eng</language><publisher>Athens: Spandidos Publications</publisher><subject>Amino acids ; Antibodies ; Apoptosis ; Cell cycle ; Cell growth ; Comparative analysis ; Hepatoma ; Kinases ; Liver cancer ; Medical prognosis ; Metabolism ; Metastasis ; Multivariate analysis ; Patients ; Prognosis ; Prostate cancer ; Protein synthesis ; Proteins ; Tumors</subject><ispartof>Oncology letters, 2022-11, Vol.24 (5), p.1, Article 418</ispartof><rights>COPYRIGHT 2022 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2022</rights><rights>Copyright: © Selenge et al. 2022</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555019/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555019/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Selenge, Baasansvren</creatorcontrib><creatorcontrib>Yamada, Shinichiro</creatorcontrib><creatorcontrib>Morine, Yuji</creatorcontrib><creatorcontrib>Ikemoto, Tetsuya</creatorcontrib><creatorcontrib>Saito, Yu</creatorcontrib><creatorcontrib>Takasu, Chie</creatorcontrib><creatorcontrib>Teraoku, Hiroki</creatorcontrib><creatorcontrib>Shimada, Mitsuo</creatorcontrib><title>Impact of L‑type amino acid transporter 3 on the prognosis of hepatocellular carcinoma</title><title>Oncology letters</title><description>The aim of the present study was to investigate the impact of L-type amino acid transporter 3 (LAT3) expression on the prognosis of hepatocellular carcinoma (HCC). A total of 135 patients who had undergone initial hepatic resection for HCC at Tokushima University Hospital (Tokushima, Japan) were enrolled in the present study. Immunohistochemical analysis of LAT3 and phosphorylated AKT (p-AKT) was performed using resected specimens. Clinicopathological factors, including prognosis, were compared between the LAT3-high and -low expression groups. The results demonstrated that the LAT3-high group showed significantly higher protein induced by vitamin K absence-II levels (P=0.01) compared with the LAT3-low group. The LAT3-high group showed significantly worse prognosis compared with the LAT3-low group regarding cancer-specific survival and disease-free survival (P<0.05). Multivariate analysis revealed that high LAT3 expression and multiple tumors were independent prognostic factors for cancer-specific survival. Furthermore, the rate of p-AKT-positive cases was higher in the LAT3-high group than in the LAT3-low group. Overall, these findings suggested that LAT3 expression was associated with poor prognosis of HCC and high p-AKT expression.</description><subject>Amino acids</subject><subject>Antibodies</subject><subject>Apoptosis</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Comparative analysis</subject><subject>Hepatoma</subject><subject>Kinases</subject><subject>Liver cancer</subject><subject>Medical prognosis</subject><subject>Metabolism</subject><subject>Metastasis</subject><subject>Multivariate analysis</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Prostate cancer</subject><subject>Protein synthesis</subject><subject>Proteins</subject><subject>Tumors</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptks1q3TAQhU1oISHJsntBoTvf6seS7U0hhP4ELnTTQHZirjS-VpAlV5IL2fUV-op9kvomIe2FSgsNmu8cZuBU1RtGN6Lr-fvoN5xyvmFCiu6kOmNtz2tGO_7qpW6b0-oy53u6HqlY16mz6u5mmsEUEgey_f3zV3mYkcDkQiRgnCUlQchzTAUTESQGUkYkc4r7ELPLB9WIM5Ro0PvFQyIGklnVE1xUrwfwGS-f3_Pq9tPHb9df6u3XzzfXV9vayIaVutn1jWVd07UUFKC1krfY0JZJxlBY2BkwXLaGUsaEtajormsE9GpgCIOl4rz68OQ7L7sJrcGwzuz1nNwE6UFHcPq4E9yo9_GH7qWUlPWrwdtngxS_L5iLvo9LCuvMmre8YaJRSv6l9uBRuzDE1cxMLht9tVJKCcUP1OY_1HotTs7EgINb_48E7_4RjAi-jDn6pbgY8jFYP4EmxZwTDi8bMqoPAdDR60MA9GMAxB-Ge6NO</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Selenge, Baasansvren</creator><creator>Yamada, Shinichiro</creator><creator>Morine, Yuji</creator><creator>Ikemoto, Tetsuya</creator><creator>Saito, Yu</creator><creator>Takasu, Chie</creator><creator>Teraoku, Hiroki</creator><creator>Shimada, Mitsuo</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20221101</creationdate><title>Impact of L‑type amino acid transporter 3 on the prognosis of hepatocellular carcinoma</title><author>Selenge, Baasansvren ; Yamada, Shinichiro ; Morine, Yuji ; Ikemoto, Tetsuya ; Saito, Yu ; Takasu, Chie ; Teraoku, Hiroki ; Shimada, Mitsuo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-4b94d184870a6aedd527e4071511e3dabcac257c00113dde60b843a96f1eafd03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Amino acids</topic><topic>Antibodies</topic><topic>Apoptosis</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Comparative analysis</topic><topic>Hepatoma</topic><topic>Kinases</topic><topic>Liver cancer</topic><topic>Medical prognosis</topic><topic>Metabolism</topic><topic>Metastasis</topic><topic>Multivariate analysis</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Prostate cancer</topic><topic>Protein synthesis</topic><topic>Proteins</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Selenge, Baasansvren</creatorcontrib><creatorcontrib>Yamada, Shinichiro</creatorcontrib><creatorcontrib>Morine, Yuji</creatorcontrib><creatorcontrib>Ikemoto, Tetsuya</creatorcontrib><creatorcontrib>Saito, Yu</creatorcontrib><creatorcontrib>Takasu, Chie</creatorcontrib><creatorcontrib>Teraoku, Hiroki</creatorcontrib><creatorcontrib>Shimada, Mitsuo</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Selenge, Baasansvren</au><au>Yamada, Shinichiro</au><au>Morine, Yuji</au><au>Ikemoto, Tetsuya</au><au>Saito, Yu</au><au>Takasu, Chie</au><au>Teraoku, Hiroki</au><au>Shimada, Mitsuo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of L‑type amino acid transporter 3 on the prognosis of hepatocellular carcinoma</atitle><jtitle>Oncology letters</jtitle><date>2022-11-01</date><risdate>2022</risdate><volume>24</volume><issue>5</issue><spage>1</spage><pages>1-</pages><artnum>418</artnum><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>The aim of the present study was to investigate the impact of L-type amino acid transporter 3 (LAT3) expression on the prognosis of hepatocellular carcinoma (HCC). A total of 135 patients who had undergone initial hepatic resection for HCC at Tokushima University Hospital (Tokushima, Japan) were enrolled in the present study. Immunohistochemical analysis of LAT3 and phosphorylated AKT (p-AKT) was performed using resected specimens. Clinicopathological factors, including prognosis, were compared between the LAT3-high and -low expression groups. The results demonstrated that the LAT3-high group showed significantly higher protein induced by vitamin K absence-II levels (P=0.01) compared with the LAT3-low group. The LAT3-high group showed significantly worse prognosis compared with the LAT3-low group regarding cancer-specific survival and disease-free survival (P<0.05). Multivariate analysis revealed that high LAT3 expression and multiple tumors were independent prognostic factors for cancer-specific survival. Furthermore, the rate of p-AKT-positive cases was higher in the LAT3-high group than in the LAT3-low group. Overall, these findings suggested that LAT3 expression was associated with poor prognosis of HCC and high p-AKT expression.</abstract><cop>Athens</cop><pub>Spandidos Publications</pub><doi>10.3892/ol.2022.13538</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2022-11, Vol.24 (5), p.1, Article 418 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9555019 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Amino acids Antibodies Apoptosis Cell cycle Cell growth Comparative analysis Hepatoma Kinases Liver cancer Medical prognosis Metabolism Metastasis Multivariate analysis Patients Prognosis Prostate cancer Protein synthesis Proteins Tumors |
| title | Impact of L‑type amino acid transporter 3 on the prognosis of hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T09%3A04%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20L%E2%80%91type%20amino%20acid%20transporter%203%20on%20the%20prognosis%20of%20hepatocellular%20carcinoma&rft.jtitle=Oncology%20letters&rft.au=Selenge,%20Baasansvren&rft.date=2022-11-01&rft.volume=24&rft.issue=5&rft.spage=1&rft.pages=1-&rft.artnum=418&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2022.13538&rft_dat=%3Cgale_pubme%3EA724663625%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2724134665&rft_id=info:pmid/&rft_galeid=A724663625&rfr_iscdi=true |